The use of selective progestin receptor modulators (<scp>SPRMs</scp>) and more specifically ulipristal acetate in the practice of gynaecology

Rozenberg, Serge; Praet, Julie; Pazzaglia, Eliza; Gilles, Christine; Manigart, Yannick; Vandromme, Jean

doi:10.1111/ajo.12641

Cited by 8 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are studies that use off-label in the treatment of endometriosis.19 When UPA (5 mg daily dose) is administered for three months before the surgery in the treatment of fibroids, it reduced vaginal bleeding and fibroid size, facilitated the operation, and helped patients (20,21). In the present study, it was shown that daily doses of 5mg and 10mg used for 3 months seem safe and effective in bleeding control (22).…”

Section: Discussionmentioning

confidence: 59%

Ulipristal Asetatın Ratlarda Oluşturulan Cerrahi Endometriozise Etkisi

Duran

Şahin

Kılınç

et al. 2022

Artuklu International Journal of Health Sciences

View full text Add to dashboard Cite

Objective: The effect of Ulipristal Acetate on endometriosis foci created in rats was investigated. Methods: The study was conducted with 12-week-old rats weighing approximately 280 grams. After creating an autologous endometriosis model, the group that did not receive ulipristal acetate negative was administered with oral saline daily, and the group given ulipristal acetate positive was administered with 0.5 mg/kg (0.125 mg/rat/day) orally for 4 weeks. Ectopic endometrial tissues were removed for histopathological and immunohistochemical evaluations. Staining was performed with Hematoxylin Eosin, Ki-67, and Cyclooxygenase-2. Results: The Hematoxylin-Eosin Staining score of the ectopic endometrium surface epithelium was found to be 2.5 points in the ulipristal acetate negative group, and 0.5 points in the ulipristal acetate positive group. In the immunohistochemical evaluation, Ki-67 positivity of the ectopic endometrial surface epithelium was found to be 71.2% in the ulipristal acetate negative group vs. 31.7% in the ulipristal acetate positive group. Cyclooxygenase-2 positivity was detected as 67% in the ulipristal acetate negative group vs. 27% in the ulipristal acetate positive group. Conclusions: Hematoxylin-Eosin staining revealed that ulipristal acetate negative group was 2.5 (well-moderately preserved epithelium), and the ulipristal acetate positive group was 0.5 (epithelium was rarely present or absent). It was found that the percentage of Ki-67 and Cyclooxygenase-2 immunohistochemical positivity was decreased in the ulipristal acetate positive group compared to the ulipristal acetate negative group at a statistically significant level. More literature data are needed on this subject.

show abstract

Section: Discussionmentioning

confidence: 59%

Ulipristal Asetatın Ratlarda Oluşturulan Cerrahi Endometriozise Etkisi

Duran

Şahin

Kılınç

et al. 2022

Artuklu International Journal of Health Sciences

View full text Add to dashboard Cite

show abstract

“…Initially, UPA have been used to reduce the fibroid volume for 3 months before surgery. However, recently, it is used in patients who refuse to remove their uterus ( Pazzaglia et al, 2017 ; Rozenberg et al, 2017 ). Due to the progesterone antagonist activity of UPA on the endometrium, this could cause an unopposed estrogen activity, which may increase cell proliferation.…”

Section: Drawbacks Of the Current Treatments For Uterine Fibroidsmentioning

confidence: 99%

Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review

et al. 2022

View full text Add to dashboard Cite

Uterine fibroids (UFs) are a common benign gynecological tumor that affect the majority of women over their lifetime. Several pharmacological agents are available to reduce the size of fibroids and ameliorate the symptoms of UF. However, these drugs are expensive and are usually associated with profound side effects. Thus, botanical drugs are gaining attention in this era due to their cost effectiveness with a comparable and more potent therapeutic efficacy while demonstrating lesser adverse effects. The objective of this review is to summarize the available information on the mechanism of various botanical drugs and polyherbal formulations with anti-uterine fibroid activity. A systematic search was performed on botanical drugs with anti-uterine fibroid activity using several search engines, which include PubMed, Google Scholar, and Science Direct. Based on the literatures identified, a total of five botanical drugs and three polyherbal formulations were included and discussed in this review, which yields useful information regarding the mechanism of different botanical drugs and polyherbal formulations in exerting anti-uterine fibroid activity for its potential use as an alternative treatment choice for uterine fibroids.

show abstract

“…Less than 6 month GnRHa is associated with limited and reversible bone loss, while GnRHa therapy for more than 6 months induces important bone loss. The current indication is severe endometriosis, before surgery or before IVF, since patients with uterine fibroids, are nowadays treated with Ulipristal acetate instead of GnRHa [115].…”

Section: Drug Inducedmentioning

confidence: 99%

How to manage osteoporosis before the age of 50

et al. 2020

View full text Add to dashboard Cite

This narrative review discusses several aspects of the management of osteoporosis in patients under 50 years of age. Peak bone mass is genetically determined but can also be affected by lifestyle factors. Puberty constitutes a vulnerable period. Idiopathic osteoporosis is a rare, heterogeneous condition in young adults due in part to decreased osteoblast function and deficient bone acquisition. There are no evidence-based treatment recommendations. Drugs use can be proposed to elderly patients at very high risk. Diagnosis and management of osteoporosis in the young can be challenging, in particular in the absence of a manifest secondary cause. Young adults with low bone mineral density (BMD) do not necessarily have osteoporosis and it is important to avoid unnecessary treatment. A determination of BMD is recommended for premenopausal women who have had a fragility fracture or who have secondary causes of osteoporosis: secondary causes of excessive bone loss need to be excluded and treatment should be targeted. Adequate calcium, vitamin D, and a healthy lifestyle should be recommended. In the absence of fractures, conservative management is generally sufficient, but in rare cases, such as chemotherapy-induced osteoporosis, antiresorptive medication can be used. Osteoporosis in young men is most often of secondary origin and hypogonadism is a major cause; testosterone replacement therapy will improve BMD in these patients. Diabetes is characterized by major alterations in bone quality, implying that medical therapy should be started sooner than for other causes of osteoporosis. Primary hyperparathyroidism, hyperthyroidism, Cushing's syndrome and growth hormone deficiency or excess affect cortical bone more often than trabecular bone. increase in bone fragility and susceptibility to fracture' [1]. Fractures in premenopausal women are less frequent than in postmenopausal women, but they may be an important indicator of underlying poor bone quality and future fracture risk [2]. According to the WHO, in postmenopausal women, osteoporosis is diagnosed when hip or spine

show abstract

The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology

Cited by 8 publications

References 40 publications

Ulipristal Asetatın Ratlarda Oluşturulan Cerrahi Endometriozise Etkisi

Ulipristal Asetatın Ratlarda Oluşturulan Cerrahi Endometriozise Etkisi

Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review

How to manage osteoporosis before the age of 50

Contact Info

Product

Resources

About